
### What is the goal of the RDB?

https://covid19researchdatabase.org

The COVID-19 Research Database seeks to accelerate the amount of real-world data that researchers can freely access to better understand and mitigate the effects of the COVID-19 pandemic. Better insights will enable faster cures, more tailored mitigation plans, and support reopening America.






Core real-world data sets that can be joined in a privacy-preserving manner

Open, scalable technology to host data, and link to any additional real-world data set






# Governance and Research Management




# Technical Infrastructure






#### Solution: The Open Research Database Stack





The COVID-19 Research Database currently covers **316,087,395** individuals with claims or electronic records (EHR) data



### **1 year post launch**



>150

~400

Researchers have registered

Research groups actively using the Research Database for a major project

Researchers have applied for access to datasets as part of research applications

## **Registered Organizations**

**Government Organizations, Non-Profits, and Labs**: CDC, NIH, FDA, VA, CBO, HHS, American Cancer Society, IHME, Autoimmune Registry, Urban Institute, NASA, EPA, Alzheimer's Association, Government Accountability Office, Pacific Northwest National Lab, Berkeley Lab, Los Alamos National Laboratory, Federal Reserve Bank

State Governments: California, Massachusetts, Michigan, Pennsylvania, Utah, Wisconsin, Virginia

**Medical Centers**: Mayo Clinic, Cleveland Clinic, and all of the top 30 medical schools according to the 2021 US News Ranking (Harvard, Johns Hopkins, Perelman (Penn), NYU, Stanford, Columbia, Mayo, UCLA, UCSF, WashU, Weill (Cornell), Duke, University of Washington, University of Pittsburgh, University of Michigan, Yale, University of Chicago, Northwestern, Vanderbilt, Icahn School, UCSD, Baylor, University of North Carolina (Chapel Hill), Case Western, Emory, University of Texas Southwestern, University of Wisconsin Madison, Oregon Health and Science University, BU, and UVA)

**Countries:** 45 different countries (Afghanistan, Algeria, Australia, Austria, Bahrain, Brazil, Bulgaria, Canada, Chile, China, Colombia, Ecuador, Egypt, England, France, Germany, Guatemala, India, Indonesia, Iran, Iraq, Italy, Japan, Kenya, Lebanon, Macedonia, Mexico, Netherlands, Nigeria, North Macedonia, Pakistan, Peru, Philippines, Portugal, Romania, Saudi Arabia, Senegal, Singapore, South Africa, Spain, Switzerland, Taiwan, United Arab Emirates, United Kingdom, United States)



# **Example Studies Submitted by Researchers**

Prediction and Treatment Recommendations for Patients with Severe COVID-19 Infection	CHICAGO
Risk of COVID-19 Amongst Lupus and Dermatomyositis Patients Taking Hydroxychloroquine	HARVARD MEDICAL SCHOOL
A Geospatial and Temporal Analysis Comparing COVID-19 Related Outcomes in Patients Routinely Treated with IL-6 inhibitors, JAK inhibitors, or Monoclonal Antibody to Patients Routinely Receiving Hydroxychloroquine.	
Surgery During the COVID19 Pandemic: A Unique Opportunity to Define US Baseline Essential Surgical Needs	Stanford University
The Prevalence of Hypercoagulopathy in COVID-19 and Potential Mitigation Strategies: A Retrospective Cohort Analysis	The University of Vermont
The Effects of COVID-19 on Health Care Utilization and Mortality	UCSF OBerkeley
The Effects of Health Insurance on COVID-19 Mortality: A Regression Discontinuity Design	Yale University